235. Hypoparathyroidism Clinical trials / Disease details
Clinical trials : 88 / Drugs : 107 - (DrugBank : 24) / Drug target genes : 5 - Drug target pathways : 7
Showing 1 to 10 of 88 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05735015 (ClinicalTrials.gov) | March 22, 2023 | 17/2/2023 | Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgical Hypoparathyroidism (PSH) Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgic ... | Phase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects With Post-Surgical Hypoparathyroidism (PSH) Phase 2 Study of the PTH-Independent Effects of Encaleret on Mineral Homeostasis in Subjects With Po ... | Post-Surgical Hypoparathyroidism | Drug: encaleret | National Institute of Dental and Craniofacial Research (NIDCR) | NULL | Not yet recruiting | 18 Years | N/A | All | 20 | Phase 2 | United States |
| 2 | NCT05654701 (ClinicalTrials.gov) | March 2023 | 8/12/2022 | Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism | Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism | Hypoparathyroidism | Drug: Palopegteriparatide (TransCon PTH) | Ascendis Pharma Bone Diseases A/S | NULL | Available | 18 Years | N/A | All | NULL | ||
| 3 | JPRN-JapicCTI-194828 | 31/8/2022 | 25/06/2019 | A Clinical Study of rhPTH (1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism | A Phase 3, Open-label Clinical Study of rhPTH (1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism A Phase 3, Open-label Clinical Study of rhPTH (1-84) Treatment in Japanese Subjects With Chronic Hyp ... | Chronic Hypoparathyroidism | Intervention name : rhPTH (1-84) INN of the intervention : Parathyroid hormone Dosage And administration of the intervention : rhPTH (1-84) will be administered at 25, 50, 75 and 100 micrograms once daily in one of the thighs (alternate thigh every day) as a subcutaneous injection. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : rhPTH(1-84) INN of the intervention : Parathyroid hormone Dosage And administratio ... | Takeda Pharmaceutical Company Limited | NULL | pending | 20 | 85 | BOTH | 12 | Phase 3 | Japan |
| 4 | NCT03878953 (ClinicalTrials.gov) | August 31, 2022 | 15/3/2019 | A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism | A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypoparathyroidism A Phase 3, Open-label Clinical Study of rhPTH(1-84) Treatment in Japanese Subjects With Chronic Hypo ... | Chronic Hypoparathyroidism | Drug: rhPTH(1-84) | Shire | NULL | Withdrawn | 20 Years | 85 Years | All | 0 | Phase 3 | Japan |
| 5 | NCT05328076 (ClinicalTrials.gov) | May 2, 2022 | 7/4/2022 | Parathyroid Vascularization During Total Thyroidectomy Using Indocyanine Green Angiography | Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indo ... | Thyroid;Thyroid Cancer;Hypoparathyroidism;Vascularization | Drug: Indocyanine green;Device: SPY Portable Handheld Imaging (SPY-PHI) | IRCCS San Raffaele | NULL | Recruiting | 18 Years | N/A | All | 66 | Italy | |
| 6 | NCT05186883 (ClinicalTrials.gov) | March 1, 2022 | 1/12/2021 | Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells | Treatment of Postoperative Hypoparathyroidism Using Cultured Allogenic Parathyroid Cells | Postoperative Hypoparathyroidism | Biological: Allogenic parathyroid cells;Other: Standard treatment according to the Clinical protocols Biological: Allogenic parathyroid cells;Other: Standard treatment according to the Clinical protocol ... | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Belarusian State Medical University | Not yet recruiting | 18 Years | 70 Years | All | 20 | Phase 1/Phase 2 | NULL |
| 7 | JPRN-jRCT2051210058 | 02/11/2021 | 30/07/2021 | A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Japanese Adults With Hypoparathyroidism A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Ja ... | A Phase 3, Multicenter, Single Arm, Open-Label Trial, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Japanese Adult Subjects with Hypoparathyroidism - PaTHway Japan Trial A Phase 3, Multicenter, Single Arm, Open-Label Trial, Investigating the Safety, Tolerability and Eff ... | Hypoparathyroidism | TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg/mL in a single-patient-use prefilled pen intended for SC injection. All subjects will start with study drug 18 microgram/day and will be administered study drug once daily subcutaneously. Subjects will be individually and progressively titrated to an optimal dose in dose increments (increase or decrease) of 3 microgram/day. TransCon PTHdrug product is supplied as a solution with a concentration of 0.3 mg/mL in a single-pat ... | Sibley Christopher | NULL | Recruiting | >= 18age old | Not applicable | Both | 12 | Phase 3 | Japan |
| 8 | NCT05117853 (ClinicalTrials.gov) | November 1, 2021 | 21/10/2021 | Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy | The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A Randomized Clinical Trial The Use of Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Total Thyroidectomy: A ... | Thyroid Disease;Hypoparathyroidism Postprocedural | Drug: Autofluorescent detection + Injection of indocyanine green;Procedure: Gold standard of visual identification and evaluation of viability of the parathyroid glands. Drug: Autofluorescent detection + Injection of indocyanine green;Procedure: Gold standard of visual ... | Onze Lieve Vrouw Hospital | NULL | Recruiting | 18 Years | N/A | All | 300 | Phase 3 | Belgium |
| 9 | NCT05387070 (ClinicalTrials.gov) | July 28, 2021 | 18/5/2022 | PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH ... | PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism PaTHway CHINA TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel ... | Hypoparathyroidism;Parathyroid Hormone Deficiency;Endocrine System Diseases;Parathyroid Diseases | Drug: TransCon PTH;Drug: placebo | Visen Pharmaceuticals (Shanghai) Co., Ltd. | NULL | Recruiting | 18 Years | N/A | All | 76 | Phase 3 | China |
| 10 | ChiCTR2100047758 | 2021-07-01 | 2021-06-26 | A medical records based study for observation of Teriparatidec in the treatment of congenital hypoparathyroidism A medical records based study for observation of Teriparatidec in the treatment of congenital hypopa ... | The observation of Teriparatide in the treatment of congenital hypoparathyroidism | Congenital Hypoparathyroidism | Teriparatide group:No;Control group:No; | The Seventh Medical Center, PLA General Hospital | NULL | Pending | 0 | 18 | Both | Teriparatide group:5;Control group:5; | China |